科兴和国药疫苗在预防拉齐奥地区（意大利）居民感染 SARS-CoV-2 方面的有效性。

Effectiveness of the Comirnaty and the Vaxzevria vaccines in preventing SARS-CoV-2 infection among residents in Lazio region (Italy).

机构信息

Local Health Unit Asl Roma 2, Rome, Italy.

出版信息

Vaccine. 2022 Apr 20;40(18):2540-2545. doi: 10.1016/j.vaccine.2022.02.063. Epub 2022 Mar 22.

DOI:10.1016/j.vaccine.2022.02.063

PMID:35341646

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8938180/

Abstract

We estimated the effectiveness of Comirnaty and Vaxzevria vaccines among 371,423 residents in Lazio Region (Italy) vaccinated since 27/12/2020, and followed until diagnosis of SARS-CoV-2 infection or 25/4/2021, whichever came first. By the end of follow-up most of the Comirnaty-cohort (60%) had received the second dose at recommended time of 21 days (98%), while the Vaxzevria-cohort had received only one dose. Adjusted hazard ratios of SARS-CoV-2 infection at weekly intervals since the first dose were estimated through a Cox regression model using 0-13 days as reference time-interval. An increase in effectiveness with increasing time since administration was observed for Comirnaty (five-weeks = 81%, 95 %CI 71-88%; three-months = 94%, 95 %CI 84-98%). One dose of Vaxzevria showed an effectiveness of 63% (95 %CI 25-82%) after 7 weeks, although further analyses are needed after complete vaccination with two doses. These results could support the ongoing vaccination campaign by reinforcing evidence-based communication aimed at reducing vaccine hesitancy.

摘要

我们在意大利拉齐奥地区（Lazio Region）对 371423 名自 2020 年 12 月 27 日以来接种疫苗的居民进行了 Comirnaty 和 Vaxzevria 疫苗有效性评估，并随访至诊断为 SARS-CoV-2 感染或 2021 年 4 月 25 日，以先发生者为准。在随访结束时，Comirnaty 组（60%）的大多数人已按建议的 21 天（98%）间隔时间接种了第二剂，而 Vaxzevria 组仅接种了一剂。通过 Cox 回归模型，使用 0-13 天作为参考时间间隔，估算了自第一剂以来每周间隔 SARS-CoV-2 感染的调整后风险比。Comirnaty 的有效性随着给药后时间的增加而增加（五周时为 81%，95%CI 71-88%；三个月时为 94%，95%CI 84-98%）。一剂 Vaxzevria 在 7 周后显示出 63%的有效性（95%CI 25-82%），尽管在两剂完全接种后需要进一步分析。这些结果可以支持正在进行的疫苗接种运动，加强基于证据的沟通，旨在减少疫苗犹豫。